The covert “C”; prevalence: Risk factors and management of hepatitis C in psychiatric in-patients

J Ramachandran; H Slattery; S Budd; T Mohan; T Cowain; A Baas; L Wigg; J Alexander; K Muller; B Kaambwa; R Woodman; A Wigg

doi:10.1016/S0168-8278(18)30543-9

The covert “C”; prevalence: Risk factors and management of hepatitis C in psychiatric in-patients

J Ramachandran
, H Slattery
, S Budd
, T Mohan
, T Cowain
, A Baas
, L Wigg
, J Alexander
, K Muller
, B Kaambwa
, R Woodman
, A Wigg

College of Medicine and Public Health

Research output: Contribution to journal › Meeting Abstract

Abstract

Background and Aims: Despite concerns about high prevalence of hepatitis C virus (HCV), psychiatry patients have been underserved due to neuropsychiatric adverse effects of interferon therapy. Directly acting antiviral (DAA) agents have made treatment of HCV in these patients feasible. In view of the paucity of information about prevalence of HCV in this group in Australia, and since an admission for mental illness may offer an opportunity for screening and treatment of HCV, this study was undertaken. Aims of this study were to assess inpatients admitted to hospital with mental illness: (1) HCV seroprevalence (2) prevalence of risk factors for HCV and (3) experience of treatment and follow-up.

Original language	English
Pages (from-to)	S165-S166
Number of pages	2
Journal	Journal of Hepatology
Volume	68
Issue number	S1
DOIs	https://doi.org/10.1016/S0168-8278(18)30543-9
Publication status	Published - Apr 2018
Event	International Liver Congress 2018 - Paris expo Porte de Versailles, Paris, France Duration: 11 Apr 2018 → 15 Apr 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Hepatitis C
Risk factors
Psychiatric inpatients
Interferon therapy

Access to Document

10.1016/S0168-8278(18)30543-9Licence: In Copyright

Cite this

@article{f9fa6fd0878341bc89b4fec9384412e7,

title = "The covert “C”; prevalence: Risk factors and management of hepatitis C in psychiatric in-patients",

abstract = "Background and Aims: Despite concerns about high prevalence of hepatitis C virus (HCV), psychiatry patients have been underserved due to neuropsychiatric adverse effects of interferon therapy. Directly acting antiviral (DAA) agents have made treatment of HCV in these patients feasible. In view of the paucity of information about prevalence of HCV in this group in Australia, and since an admission for mental illness may offer an opportunity for screening and treatment of HCV, this study was undertaken. Aims of this study were to assess inpatients admitted to hospital with mental illness: (1) HCV seroprevalence (2) prevalence of risk factors for HCV and (3) experience of treatment and follow-up.",

keywords = "Hepatitis C, Risk factors, Psychiatric inpatients, Interferon therapy",

author = "J Ramachandran and H Slattery and S Budd and T Mohan and T Cowain and A Baas and L Wigg and J Alexander and K Muller and B Kaambwa and R Woodman and A Wigg",

year = "2018",

month = apr,

doi = "10.1016/S0168-8278(18)30543-9",

language = "English",

volume = "68",

pages = "S165--S166",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

number = "S1",

note = "International Liver Congress 2018 ; Conference date: 11-04-2018 Through 15-04-2018",

}

TY - JOUR

T1 - The covert “C”; prevalence

T2 - International Liver Congress 2018

AU - Ramachandran, J

AU - Slattery, H

AU - Budd, S

AU - Mohan, T

AU - Cowain, T

AU - Baas, A

AU - Wigg, L

AU - Alexander, J

AU - Muller, K

AU - Kaambwa, B

AU - Woodman, R

AU - Wigg, A

PY - 2018/4

Y1 - 2018/4

N2 - Background and Aims: Despite concerns about high prevalence of hepatitis C virus (HCV), psychiatry patients have been underserved due to neuropsychiatric adverse effects of interferon therapy. Directly acting antiviral (DAA) agents have made treatment of HCV in these patients feasible. In view of the paucity of information about prevalence of HCV in this group in Australia, and since an admission for mental illness may offer an opportunity for screening and treatment of HCV, this study was undertaken. Aims of this study were to assess inpatients admitted to hospital with mental illness: (1) HCV seroprevalence (2) prevalence of risk factors for HCV and (3) experience of treatment and follow-up.

AB - Background and Aims: Despite concerns about high prevalence of hepatitis C virus (HCV), psychiatry patients have been underserved due to neuropsychiatric adverse effects of interferon therapy. Directly acting antiviral (DAA) agents have made treatment of HCV in these patients feasible. In view of the paucity of information about prevalence of HCV in this group in Australia, and since an admission for mental illness may offer an opportunity for screening and treatment of HCV, this study was undertaken. Aims of this study were to assess inpatients admitted to hospital with mental illness: (1) HCV seroprevalence (2) prevalence of risk factors for HCV and (3) experience of treatment and follow-up.

KW - Hepatitis C

KW - Risk factors

KW - Psychiatric inpatients

KW - Interferon therapy

U2 - 10.1016/S0168-8278(18)30543-9

DO - 10.1016/S0168-8278(18)30543-9

M3 - Meeting Abstract

SN - 0168-8278

VL - 68

SP - S165-S166

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - S1

Y2 - 11 April 2018 through 15 April 2018

ER -

The covert “C”; prevalence: Risk factors and management of hepatitis C in psychiatric in-patients

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this